One thing we have learned from the news that Perrigo and Galderma are embarking on a patent dispute, is how successful Soolantra has been as a product.
Perrigo Confirms Patent Challenge For Generic Version Of Soolantra Cream, 1%
Soolantra (ivermectin) cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Annual market sales for the 12 months ending May 2017 were $87 million.
So sales of Soolantra are already approaching $100m a year.
[Update January 2018:] We now know that Soolantra has a $120m a year run rate from a further press release from Perrigo.
